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Abstract Hypersecretionof airwaymucusis a characteristic feature ofchronic airwaydiseaseslike cystic ¢brosis (CF)
andleadsvia impairmentofthemuco-ciliaryclearance andbacterial superinfectiontorespiratory failure.Themajor com-
ponents of the mucusmatrix forming family of mucins in the airways are MUC5AC and MUC5B.To investigate the ex-
pression of these glycoproteins in CF, immunohistochemistry was carried out on trachea, bronchi and peripheral lung
obtained fromCF patients andcomparedtonormallung tissues.MUC5ACimmunohistochemistrydemonstrated signals
in gobletcells of the epithelial lining.Also, gobletcells inside glandular secretoryducts revealed MUC5AC-positive stain-
ing. In comparison to those from normal subjects,CF sections were characterized by in£ammatory changes and goblet
cell hyperplasia, resulting in increased numbers of MUC5AC-positive cells. Immunohistochemical staining for MUC5B
showed abundant staining of submucosal glands and epithelial goblet cells. Inside the glands, the immunoreactivity was
restricted to glandular mucous cells.MUC5AC and MUC5B are expressed in the same histological pattern in CF com-
pared to normal tissues with an increase of MUC5AC-positive cells due to goblet cell hyper- and metaplasia.
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Cystic ¢brosis (CF), a common inherited, autosomal re-
cessive disorder, is causedby a dysfunction of the epithe-
lial chloride channel CF transmembrane regulator
(CFTR) (1). So far, more than 500mutations of theCFTR
gene are known that are associated with CF (2). Apart
from gastrointestinal manifestations such as pancreatic
insu⁄ciency, the major cause of morbidity results from
airway disease (1). The hypersecretory-induced airway
changes in CF are characterized by submucosal glandReceived 22 June 2001, acceptedandrevised form5September 2001and
published online12 December 2001.
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f.chung@ic.ac.ukand goblet cell hyper- and metaplasia, leading to mucus
over-production and distortion of the muco-ciliary
clearance. As a result, airway plugging by mucus leads
to chronic in£ammatory changes and bacterial coloniza-
tion (3).
The polymer matrix of airway mucus is made
up of large, oligomeric, gel-forming glycoproteins qmu-
cins with molar masses ranging between 10 and
40 million Da (4^7). Seven di¡erent mucin apo-proteins
which are products of di¡erent genes, have been
identi¢ed in the respiratory tract so far (5). The
mucins are produced primarily by two di¡erent airway
cell types: goblet cells and glandular cells. While
MUC2 and MUC5AC expression has been localized to
cells of the surface epithelium (9,10), MUC5B and MUC7
mucins are expressed in glandular cells (11,12).Out of the
seven mucins, MUC5AC and MUC5B have been identi-
82 RESPIRATORYMEDICINE¢ed as major gel-forming macromolecules, whereas
MUC2 contributes only to a lesser extend to the
matrix (13,14).
In view of the high levels of CFTR expression in gland-
ular cells which play an important role in the composi-
tion of mucus hydration and their attributed
pathophysiological importance in the progression of CF
(15), numerous studies have focused on the identi¢cation
of di¡erences between CF and normal airway secretions
(16^19). Alterations such as increased sulphation and fu-
cosylation and decreased sialylation of secreted mucins
have been demonstrated. Biochemical studies also indi-
cated a higher heterogeneity of CF mucins in mucus as
compared to the normalmucus composition (20).
Pseudomonas aeruginosa infections play a central role
in the progression of respiratory failure in CF (21). Be-
cause P. aeruginosa exoproducts may up-regulate the ex-
pression of mucin genes (22^24), the present study was
carried out to determine whether there are changes in
the pattern and extent of distrubution of the two major
airway mucins, MUC5AC and MUC5B, in airway tissues




CF tissues fromexplanted lungswere obtained fromcys-
tic ¢brosis patients (n=6) who had lung transplantation
due to progressive respiratory failure. Tracheal (n=3),
bronchial (n=4) and peripheral lung (n=3) sections were
subjected to immunohistochemistry and compared to
sections of normal human lung tissues from patients
(n=3)who diedwithoutpulmonary involvement.The tis-
sues were either para⁄n-embedded or frozen in liquid
nitrogen-cooled isopentane.
Antibodies
One polyclonal antibody against MUC5AC, and one
polyclonal and onemonoclonal antibody against MUC5B
were used. The rabbit polyclonal anti-MUC5AC serum
(LUM5-1) was raised against a keyhole limpet haemo-
cyanin-conjugated synthetic peptide (sequence
RNQDQQGPFKMC) that is present in the carboxy-
terminal region and two stretches £anking a tandem re-
peat region of MUC5AC (9). A rabbit polyclonal anti-
MUC5B (LUM5B-2) serum was raised against the se-
quence RNREQVGKFKMC which is present in the cen-
tral region of the MUC5B apoprotein (12) and compared
to a mouse monoclonal antibody (11C1) against MUC5B
(25). Both polyclonal antibodies were characterized re-
cently: preabsorption studies with increasing concentra-
tions of the mucins con¢rmed the speci¢ty of the
antibodies (9,12).Immunohistochemistry
For immunohistochemistry, 6^8mm sections of frozen
tissues were cut on a cryostat, mounted on gelatin-
coated glass slides and air dried for 1h. Alternatively,
6mm para⁄n-embedded sections were cut on a micro-
tome, depara⁄nized through 100% xylene and rehy-
drated through graded alcohol series. After rinsing in
phosphate-bu¡ered saline (PBS), the sections were im-
mersion-¢xed in 50% acetone 50% methanol for 20min
and washed in PBS twice for 5min. Endogenous peroxi-
dase activity was quenched by incubation with 0.3%
H2O2 for 30min followed by rinses in PBS. Then,
non-speci¢c labelling was blocked by coating with
preincubation serum (0.1M phosphate bu¡er containing
1% bovine serum albumin and10% normal swine serum)
for 1h at room temperature. After washing in PBS, the
tissues were incubated with either the polyclonal rabbit
anti-MUC5AC-serum (9) diluted1:1000 in the preincuba-
tion solution, the polyclonal rabbit anti-MUC5B-serum
(12) diluted1:200 or themonoclonalmouse-anti-MUC5B
serum (25) diluted 1:2000 for 2h at room temperature.
After incubation and repeated washing steps with PBS,
the sections incubated with the polyclonal rabbit pri-
mary antisera were subsequently treated with biotiny-
lated goat anti-rabbit IgG (diluted 1:75 in preincubation
serum; Vectastain Elite ABC,Vector Laboratories, Bur-
lingame,CA,U.S.A) and the sections incubated with the
monoclonal mouse antibody were treated with biotiny-
latedhorse anti-mouse IgG (diluted1:75 in preincubation
serum, Vectastain ABC, Vector Laboratories, for 1h at
room temperature. After repeated washing steps, sec-
ondary antibodies were detected with the Vectastatin
ABCreagent in combinationwithDAB substrate (Sigma,
Poole, Dorset, U.K.). Slides were counterstained with
haematoxylin, mounted in carbonate-bu¡ered glycerol
(pH 8.6) and viewedusing a Zeissmicroscope.
RESULTS
Localization of MUC5ACA
immunoreactivity in CF andnormal tissues
MUC5AC immunohistochemistry resulted in abundant
staining of tracheal and bronchial sections. Peripheral
lung tissue was negative.MUC5AC-immunoreactivity in
trachea and bronchi was restricted to the epithelial lin-
ing. In normal tissues, the positive cells were a minority
of the epithelial cells which could be identi¢ed as goblet
cells by their characteristicmorphology [Fig.1 (b)]. Com-
parison with periodic Schi¡ acid (PAS) staining demon-
strated that all goblet cells within the surface epithelium
displayed MUC5AC reactivity. The immunoreactivity
was intense and of a non-granular type, and was not as-
sociated to the cellular membrane or to any speci¢c in-
tracellular organelle pattern.Goblet cells inside glandular
Fig. 1. Cellular localization of MUC5AC immunoreactivity in CF and normal human lung sections. MUC5AC immunoreactivity is
localized to goblet cells of CF trachea (a, c), and CF (d) and normal bronchi (b).There are increased numbers of goblet cells, positive
for MUC5ACin CF (c, d) as compared to normaltissue (b).Buttherewasno detectable reactivityin submucosalglands (e) and periph-
erallung (f). lu: airwaylumen, ep: epitheliallining, gl: glands, ct: cartilage.Bar=105 mm (a),45 mm (b,c,d), 35 mm(e) and 60 mm (f).
MUCINEXPRESSIONINCYSTICFIBROSISLUNG 83secretory ducts also revealed MUC5AC positive stain-
ing.Comparison between samples from normal subjects
[Fig. 1(b)] and those from patients with cystic ¢brosis
[Fig. 1 (a,c,d)] revealed that there was no change in the
cellular distribution of MUC5AC immunoreactivity
although, parallel to the increased number of goblet cells
due to hyperplasia, MUC5AC immunoreactivity was in-
creased compared to normal conditions [Fig.1 (b)].
LocalizationofMUC5Bimmunoreactivity in
CF andnormal tissues
Immunohistochemistry forMUC5B resultedin abundant
staining of submucosalglands.The immunoreactivity was
restricted to glandularmucous cells and epithelial goblet
cells [Fig. 2 (a^ e)].Themorphology of the MUC5B-posi-tive cellswas characteristic formucus cellswithbasal nu-
clei in comparison to serous cells [Fig. 2 (b)]. There was
MUC5B-positive mucus present in the lumen of secre-
tory ducts [Fig. 3(b)].There was no di¡erence in the dis-
tribution of glandular MUC5B immunoreactivity
between CF [Fig. 2 (a, c)] and non-CF tissues [Fig. 2(b)].
Themono-and polyclonal antibodies against MUC5B did
not di¡er in the staining pattern of MUC5B-reactive
cells.
DISCUSSION
The primary causes ofmorbidity andmortality in CF are
pulmonary obstruction and bronchiectasis, leading to
persistent bacterial infection and respiratory failure.
Fig. 2. LocalizationofMUC5Bimmunoreactivityin CFandnormalhumanlung.Sections 8 mmof CF (a, c, e, f) andnormal (b, d) lung
tissueswereincubatedwithMUC5Bantisera.Speci¢cMUC5Bimmunoreactivityispresentinmucouscells (arrowsinb) butnot serous
cells (arrowheadsinb) of submucosalglandsinCF (a, c), normaltissues (b) andinepithelialcells (e).Therewasno di¡erenceinexpression
between CF (a, c) andnormalglands (b).Negative CF peripherallung (F). lu: airwaylumen, ep: epitheliallining, gl: glands.Bar=105 mm
(a),60 mm (b, e, f), 35 mm (c, d,).
84 RESPIRATORYMEDICINEThe obstructive component of the disease is caused by a
distortion of themuco-ciliary clearance and abnormality
of the properties of the mucus leading to persistent air-
wayblockage. So far, it is not knownwhether the hyper-
secretion and alteration of mucus consistency is
paralleled by an up-regulated expression of mucin-en-
coding genes.
Previously, several mucin gene products were identi-
¢ed in the respiratory systemunder normal andpatholo-
gical conditions. MUC2 was localized to basal epithelial
and glandular duct cells but not to goblet cells or secre-
tory acini (10,26,27). A signi¢cantlygreater proportion of
the surface epithelium was positive for MUC2 gene ex-
pression in CF tissues compared to normal lungs (10).
Whereas MUC4, MUC5B, MUC5C and MUC7 gene ex-pression was localized to gland acinar cells (27), MUC1
gene expression was reported to be present in periph-
eral lung sections (28). For MUC5B and MUC7 protein
expression, studies on normal and CF bronchi revealed
an expression of MUC5B restricted to glandularmucous
cells and of MUC7 restricted to a subpopulation of ser-
ous cells (11).
Following the characterization of MUC5AC and
MUC5B as major components of tracheobronchial se-
cretions (14,29), we investigated the expression of these
mucins in CF and normal tracheal, bronchial and periph-
eral lung tissues by immunohistochemistry. We found
that MUC5AC is expressed in goblet cells of the surface
epithelial lining and also in goblet cells in ducts of glands.
This observation for normal bronchial and tracheal tis-
Fig. 3 Comparison of MUC5AC and MUC5B expression in
parallel sections oftrachea.Alternate incubationwithMUC5AC
and MUC5B antiserum of parallel sections demonstrated mu-
tual exclusive expression of the two mucin genes. Positive mu-
cous gland cells for MUC5B (arrows in b) in comparison to
negative glands for MUC5AC (a) in CF tissues. In the lumen of a
secretory duct, MUC5B-but not MUC5AC-positive mucus is
present (*). Serous cells do notdisplay MUC5Bimmunoreactiv-
ity (arrowheads).Ct: cartilage.Bar=105 mm.
MUCINEXPRESSIONINCYSTICFIBROSISLUNG 85sues is con¢rmed by a previous localization of MUC5AC
to goblet cells of tracheal tissue from a single individual
(9). In contrast,MUC5Bwas expressedmainly inmucous
cells of submucosal glands and to a lesser extent in
epithelial goblet cells.This distribution is consistent with
a report on the localization of MUC5B tomucous cells of
submandibular, sublingual and labial glands (29). Our re-
sults indicate that MUC5AC and MUC5B are expressed
by di¡erentmucus-producing airway cell types.Together
with the ¢nding that MUC7 is produced in serous gland-
ular cells (27), the di¡erential cellular partitioning ofmu-
cin gene expression underlines the diversity of airway
mucus production. Recently, MUC5B and MUC5AC but
notMUC2were identi¢ed tobe themainmatrix forming
components of the gel phase of CF sputum. MUC5ACwas enriched in the sol indicating that it may be more
susceptible to proteolytic degradation than MUC5B
(14).Themucin pattern in the sputumdidnot alter signi¢-
cantly in acute in£ammatory exacerbation or following
antibiotic treatment (14).
Although numerous studies have characterized
changes in the composition of secreted airwaymucins in
health and disease, there have been no detailed studies
investigating whether these changes re£ect changes
andplasticity of the cellular phenotypes ofmucin-secret-
ing cells or changes in the numbers of these cells. Our
results indicate no signi¢cant qualitative di¡erences in
the pattern of expression of MUC5AC and MUC5B be-
tween CF and normal lung.However, due to thewell-de-
¢ned goblet cell hyper- and metaplasia in CF, the
MUC5AC expressing cellular compartment appeared to
bemore abundant. In conclusion,MUC5AC and MUC5B
are di¡erentially expressed in goblet cells and submuco-
sal glandular mucous cells. In comparison to normal con-
ditions, CF tissues which are characterized by
in£ammatory changes displayed an increased number of
MUC5AC-positive staining due to goblet cell hyper- and
metaplasia. Also, there was increased MUC5B positive
mucus present in the airway epithelial lining, possibly re-
presenting attached mucus.Qualitatively, MUC5AC and
MUC5B are expressed in a similar histological pattern in
CF and normal tissues.
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